Nov 15, 2021
In this “Ask Me Anything” (AMA)
episode, Peter and Bob discuss all things related to GLP-1
agonists—a class of drugs that are gaining popularity for the
treatment of obesity. They cover the discovery of these peptides,
their physiology, and what it is they do in their natural state.
Next, Peter and Bob break down a recently published study which
showed remarkable results for weight loss and other metabolic
parameters using a once-weekly injection of the GLP-1 agonist drug
semaglutide, also known as Ozempic, in overweight and obese
patients. Finally, they compare results from the semaglutide study
to results from various lifestyle interventions and give their take
on the potential future of GLP-1 agonists.
If you’re not a
subscriber and listening on a podcast player, you’ll only be able
to hear a preview of the AMA. If you’re a subscriber, you can now
listen to this full episode on your private
RSS feed or on our website at the AMA #29 show notes page. If
you are not a subscriber, you can learn more about the subscriber
benefits here.
We
discuss:
- Remarkable results of a recent
study in overweight adults [2:15];
- Key background on insulin,
glucagon and the incretin effect [4:00];
- What is GLP-1 and how does it
work? [16:30];
- 2021 semaglutide study:
remarkable results, side effects, and open questions
[30:00];
- Semaglutide vs. lifestyle
interventions: comparing
results with semaglutide vs. lifestyle
interventions alone [44:00];
- Closing thoughts and open
questions on the therapeutic potential of semaglutide
[47:30]; and
- More
Show notes page for this episode: https://peterattiamd.com/ama29/
Subscribe to receive exclusive subscriber-only content: https://peterattiamd.com/subscribe/
Sign up to receive Peter's email newsletter: https://peterattiamd.com/newsletter/
Connect with Peter on Facebook | Twitter | Instagram.